Peter C Taylor (P C Taylor)

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 69

Top Topics

Rheumatoid Arthritis

Top Venues

Annals of the rheumatic diseases

Rheumatology and therapy

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Peter C Taylor, Georg Schett, Thomas Wj Huizinga, Qingmin Wang, Fowzia Ibrahim, Bei Zhou, Sophia G Liva, Jafar Sadik B Shaik, Yuan Xiong, Jocelyn H Leu, Rohit A Panchakshari, Matthew J Loza, Keying Ma, Harman Dhatt, Ricardo Rojo Cella, Chetan S Karyekar, Carolyn A Cuff, Sheng Gao, Kaiyin Fei
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD open 10 (2) (2024)
Peter C Taylor, Bryan Downie, Ling Han, Rachael Hawtin, Angie Hertz, Robert John Moots, Tsutomu Takeuchi
Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis. Rheumatology and therapy (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Arthur Kavanaugh, Peter Nash, Janet E Pope, Georg Pongratz, Bruno Fautrel, Rieke E Alten, Ken Hasegawa, Shangbang Rao, Dick de Vries, Pieter-Jan Stiers, Chris Watson, René Westhovens
Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD open 10 (1) (2024)
Peter C Taylor, Georg Schett, Thomas Wj Huizinga, Qingmin Wang, Fowzia Ibrahim, Bei Zhou, Sophia G Liva, Jafar Sadik B Shaik, Yuan Xiong, Jocelyn H Leu, Rohit A Panchakshari, Matthew J Loza, Keying Ma, Harman Dhatt, Ricardo Rojo Cella, Chetan S Karyekar, Carolyn A Cuff, Sheng Gao, Kaiyin Fei
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD open 10 (2) (2024)
Peter C Taylor
The Rheumatoid Arthritis Impact of Disease (RAID) Score in Telemedicine Management of Rheumatoid Arthritis. The Journal of rheumatology (2024)
Peter C Taylor, Georg Schett, Thomas Wj Huizinga, Qingmin Wang, Fowzia Ibrahim, Bei Zhou, Sophia G Liva, Jafar Sadik B Shaik, Yuan Xiong, Jocelyn H Leu, Rohit A Panchakshari, Matthew J Loza, Keying Ma, Harman Dhatt, Ricardo Rojo Cella, Chetan S Karyekar, Carolyn A Cuff, Sheng Gao, Kaiyin Fei
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD open 10 (2) (2024)
Line Uhrenholt, Mads E R Sørensen, Karen B Lauridsen, Kirsten Duch, Lene Dreyer, Robin Christensen, Ellen Margrethe Hauge, Anne Gitte Loft, Mads N B Rasch, Hans Christian Horn, Peter C Taylor, Kaspar René Nielsen, Salome Kristensen
Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial. Rheumatology international (2024)
Christoph Baerwald, Edgar Stemmler, Sixten Gnüchtel, Katharina Jeromin, Björn Fritz, Michael Bernateck, Daniela Adolf, Peter C Taylor, Ralf Baron
Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain. Annals of the rheumatic diseases (2024)
Peter C Taylor, Georg Schett, Thomas Wj Huizinga, Qingmin Wang, Fowzia Ibrahim, Bei Zhou, Sophia G Liva, Jafar Sadik B Shaik, Yuan Xiong, Jocelyn H Leu, Rohit A Panchakshari, Matthew J Loza, Keying Ma, Harman Dhatt, Ricardo Rojo Cella, Chetan S Karyekar, Carolyn A Cuff, Sheng Gao, Kaiyin Fei
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD open 10 (2) (2024)
Peter C Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M Xavier, John D Isaacs, Sander Strengholt, Julie M Parmentier, Ralph Lippe, Yoshiya Tanaka
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford, England) (2023)
Line Uhrenholt, Robin Christensen, Lene Dreyer, Ellen Margrethe Hauge, A Schlemmer, Anne Gitte Loft, Mnb Rasch, Hans Christian Horn, K H Gade, René Drage Østgård, Peter C Taylor, Kirsten Duch, Salome Kristensen
Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial. Scandinavian journal of rheumatology (2023)
Yoshiya Tanaka, Tsutomu Takeuchi, Derek Haaland, Stephen Hall, Güzide Nevsun İnanç, Zhanguo Li, Ricardo Machado Xavier, Carlos Cara, Nicola Tilt, Peter C Taylor
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials. International journal of rheumatic diseases (2023)
Peter C Taylor, Cedric Laedermann, Rieke Alten, Eugen Feist, Ernest Choy, Ewa Haladyj, Inmaculada De La Torre, Pascal Richette, Axel Finckh, Yoshiya Tanaka
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience. Journal of clinical medicine 12 (13) (2023)
Peter C Taylor, Yuri Sanchez Gonzalez, Ryan Clark, Freddy Faccin, Oliver Howell
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries. Rheumatology and therapy 10 (2) (2023)
Yoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate. Rheumatology and therapy (2023)
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lara Fallon, Yves Brault, Satrajit Roychoudhury, Lisy Wang, Meriem Kessouri
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD open 8 (2) (2023)
Thomas Bieber, Eugen Feist, Alan D Irvine, Masayoshi Harigai, Ewa Haladyj, Susan Ball, Walter Deberdt, Maher Issa, Susanne Grond, Peter C Taylor
Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Advances in therapy (2023)
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lara Fallon, Yves Brault, Satrajit Roychoudhury, Lisy Wang, Meriem Kessouri
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD open 8 (2) (2023)
Peter C Taylor, Ayman Askari, Ernest H S Choy, Michael R Ehrenstein, Sara Else, Muhammad K Nisar
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC medicine 21 (1) (2023)
Peter C Taylor, Ayman Askari, Ernest H S Choy, Michael R Ehrenstein, Sara Else, Muhammad K Nisar
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC medicine 21 (1) (2023)
Peter C Taylor, Ayman Askari, Ernest H S Choy, Michael R Ehrenstein, Sara Else, Muhammad K Nisar
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC medicine 21 (1) (2023)
Peter C Taylor, Yuri Sanchez Gonzalez, Ryan Clark, Freddy Faccin, Oliver Howell
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries. Rheumatology and therapy (2023)
Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haladyj, Inmaculada De La Torre, Susanne Grond, Andreas Wollenberg
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications. Advances in therapy (2023)
Peter C Taylor, Michael E Weinblatt, Iain B McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A Schifano, Celia Shelton, Julia E Smith, Millie Wang, Reena Wang, Sarah Watts, Roy M Fleischmann
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Annals of the rheumatic diseases (2023)
Peter C Taylor, Yuri Sanchez Gonzalez, Ryan Clark, Freddy Faccin, Oliver Howell
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries. Rheumatology and therapy 10 (2) (2023)
Yoshiya Tanaka, Peter C Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate. Rheumatology and therapy (2023)
Maxime Dougados, Peter C Taylor, Clifton O Bingham, Lara Fallon, Yves Brault, Satrajit Roychoudhury, Lisy Wang, Meriem Kessouri
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD open 8 (2) (2023)
Kelsey N Thompson, Kevin S Bonham, Nicholas Edward Ilott, Graham J Britton, Paula Colmenero, Samuel J Bullers, Lauren J McIver, Siyuan Ma, Long H Nguyen, Andrew Filer, India Brough, Claire F Pearson, Caroline Moussa, Vinod Kumar, Lilian H Lam, Matthew A Jackson, April Pawluk, null null, Serafim Kiriakidis, Peter C Taylor, Lucy R Wedderburn, Brian D Marsden, Stephen P Young, Dan R Littman, Jeremiah J Faith, Arthur G Pratt, Paul Bowness, Karim Raza, Fiona M Powrie, Curtis Huttenhower, null null
Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes. Science translational medicine 15 (706) (2023)
Peter C Taylor, Ayman Askari, Ernest H S Choy, Michael R Ehrenstein, Sara Else, Muhammad K Nisar
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. BMC medicine 21 (1) (2023)
Peter C Taylor, Yuri Sanchez Gonzalez, Ryan Clark, Freddy Faccin, Oliver Howell
Outcomes Following Adalimumab Bio-originator to Biosimilar Switch-A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries. Rheumatology and therapy (2023)
Roy M Fleischmann, Désirée Mfm van der Heijde, Vibeke Strand, Tatsuya Atsumi, Iain B McInnes, Tsutomu Takeuchi, Peter C Taylor, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A Schifano, Celia Shelton, Julia E Smith, Millie Wang, Reena Wang, Sarah Watts, Michael E Weinblatt
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Annals of the rheumatic diseases (2023)
Peter C Taylor
Are TNF inhibitors still the agent of choice for RA? Nature reviews. Rheumatology (2023)
Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haladyj, Inmaculada De La Torre, Susanne Grond, Andreas Wollenberg
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications. Advances in therapy (2023)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Thomas Bieber, Eugen Feist, Alan D Irvine, Masayoshi Harigai, Ewa Haladyj, Susan Ball, Walter Deberdt, Maher Issa, Susanne Grond, Peter C Taylor
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Advances in therapy 39 (11) (2022)
Kayoko Kaneko, Daniel Prieto Alhambra, Clare Jacklin, Ailsa Bosworth, Sally Dickinson, Sarah Berry, Helen McAteer, Peter C Taylor
Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations. BMJ open 12 (2) (2022)
Peter C Taylor
The Opportunities and Challenges of Telemedicine in the Management of People With Rheumatoid Arthritis. The Journal of rheumatology 49 (11) (2022)
Peter C Taylor, Mart Van de Laar, Andrew Laster, Walid Fakhouri, Amanda Quebe, Inmaculada de la Torre, Saundra Jain
Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis-going beyond treat to target. RMD open 7 (3) (2022)
Peter C Taylor, Marco Matucci Cerinic, Rieke Alten, Jérôme Avouac, Rene Westhovens
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes. Therapeutic advances in musculoskeletal disease 14 (2022)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Peter C Taylor, Rieke E Alten, Jose María Álvaro Gracia, Yuko Kaneko, Chad Walls, Amanda Quebe, Bochao Jia, Natalia Bello, Jorge Ross Terres, Roy M Fleischmann
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD open 8 (1) (2022)
Peter C Taylor, Bruno Fautrel, Yves Piette, Susana Romero-Yuste, Jasper Broen, Martin Welcker, Oliver Howell, Elke Rottier, Monia Zignani, Katrien Van Beneden, Roberto Caporali, Rieke E Alten
Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD open 8 (2) (2022)
Peter C Taylor, Andrew G Bushmakin, Joseph Christopher Cappelleri, Pamela Young, Rebecca Germino, Joseph Frank Merola, Gil Yosipovitch
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. The Journal of dermatological treatment 33 (5) (2022)
Peter C Taylor, Andrew C Adams, Matthew M Hufford, Inmaculada de la Torre, Kevin Winthrop, Robert L Gottlieb
Neutralizing monoclonal antibodies for treatment of COVID-19. Nature reviews. Immunology 21 (6) (2021)
Peter C Taylor, Codrina Ancuta, Orsolya Nagy, María C de la Vega, Andrey Gordeev, Radka Janková, Umut Kalyoncu, Ivan Lagunes-Galindo, Jadranka Morović-Vergles, Mariana Peixoto G U E Silva de Souza, Bernadette Rojkovich, Prodromos Sidiropoulos, Atsushi Kawakami
Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. Patient preference and adherence 15 (2021)
Peter C Taylor, Matthew Woods, Catherine Rycroft, Priya Patel, Sophee Blanthorn-Hazell, Toby Kent, Marwan Bukhari
Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. Rheumatology (Oxford, England) 60 (11) (2021)
Josef S Smolen, Li Xie, Bochao Jia, Peter C Taylor, Gerd Burmester, Yoshiya Tanaka, Ayesha Elias, Anabela Cardoso, Rob Ortmann, Chad Walls, Maxime Dougados
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. Rheumatology (Oxford, England) 60 (5) (2021)
Peter C Taylor, Robin Christensen, Shahrzad Moosavi, Pamela Selema, Ruffy Guilatco, Heather Fowler, Markus Mueller, Katherine F Liau, Boulos Haraoui
Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). Rheumatology advances in practice 5 (2) (2021)
Peter C Taylor, Tsutomu Takeuchi, Gerd-Rüdiger R Burmester, Patrick Durez, Josef S Smolen, Walter Deberdt, Maher Issa, Jorge Ross Terres, Natalia Bello, Kevin L Winthrop
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Annals of the rheumatic diseases (2021)
Esben Malm, Sabrina Mai Nielsen, Johannes Berg, John P A Ioannidis, Daniel Furst, Josef S Smolen, Peter C Taylor, Lars Erik Kristensen, Simon Tarp, Torkell J Ellingsen, Robin Christensen
Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. BMJ open 11 (9) (2021)
Peter C Taylor, Andrew G Bushmakin, Joseph C Cappelleri, Pamela Young, Rebecca Germino, Joseph F Merola, Gil Yosipovitch
Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis. Journal of clinical medicine 10 (18) (2021)
Peter C Taylor, Désirée Mfm van der Heijde, Robert B M Landewe, Shannon McCue, Sue Cheng, Annelies Boonen
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. The Journal of rheumatology 48 (8) (2021)
Peter C Taylor, Fabiola Atzeni, Alejandro Balsa, Laure Gossec, Ulf Müller-Ladner, Janet Pope
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. Journal of clinical medicine 10 (3) (2021)
Peter C Taylor
Adopting PROs in virtual and outpatient management of RA. Nature reviews. Rheumatology 16 (9) (2020)
Peter C Taylor, Neil Betteridge, T Michelle Brown, John Woolcott, Alan J Kivitz, Cristiano Zerbini, Diane Whalley, Oyebimpe Olayinka-Amao, Connie Chen, Palle Dahl, Dario Ponce de Leon, David Gruben, Lara Fallon
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making. Patient preference and adherence 14 (2020)
Peter C Taylor, Alejandro Balsa, Anne-Barbara Mongey, Jerome Avouac, Hubert Marotte, Rudiger B Mueller
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. Journal of clinical medicine 8 (4) (2019)
Gloria Lliso-Ribera, Frances Humby, Myles J Lewis, Alessandra Nerviani, Daniele Mauro, Felice Rivellese, Stephen Kelly, Rebecca Hands, Fabiola Bene, Nandhini Ramamoorthi, Jason A Hackney, Alberto Cauli, Ernest H Choy, Andrew Filer, Peter C Taylor, Iain McInnes, Michael J Townsend, Costantino Pitzalis
Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Annals of the rheumatic diseases 78 (12) (2019)
Yoshiya Tanaka, Bruno Fautrel, Edward C Keystone, Robert A Ortmann, Li Xie, Baojin Zhu, Maher Issa, Himanshu Patel, Carol L Gaich, Stephanie de Bono, Terence P Rooney, Peter C Taylor
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Annals of the rheumatic diseases 78 (7) (2019)
Peter C Taylor, Didier Saurigny, Jiri Vencovsky, Tsutomu Takeuchi, Tadashi Nakamura, Galina Matsievskaia, Barbara Hunt, Thomas Wagner, Bernard Souberbielle, null null
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis research & therapy 21 (1) (2019)
Frances Humby, Myles J Lewis, Nandhini Ramamoorthi, Jason A Hackney, Michael R Barnes, Michele Bombardieri, A Francesca Setiadi, Stephen Kelly, Fabiola Bene, Maria DiCicco, Sudeh Riahi, Vidalba Rocher, Nora Ng, Ilias Lazarou, Rebecca Hands, Désirée Mfm van der Heijde, Robert B M Landewé, Annette van der Helm-van Mil, Alberto Cauli, Iain McInnes, Christopher Dominic Buckley, Ernest H Choy, Peter C Taylor, Michael J Townsend, Costantino Pitzalis
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the rheumatic diseases 78 (6) (2019)
Peter C Taylor, Yvonne C Lee, Roy Fleischmann, Tsutomu Takeuchi, Elizabeth L Perkins, Bruno Fautrel, Baojin Zhu, Amanda K Quebe, Carol L Gaich, Xiang Zhang, Christina L Dickson, Douglas E Schlichting, Himanshu Patel, Frederick Durand, Paul Emery
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. Journal of clinical medicine 8 (6) (2019)
Sophie Glatt, Peter C Taylor, Iain B McInnes, Larissa Valor-Méndez, Robert Landewé, Dominique Baeten, Lucian Ionescu, Foteini Strimenopoulou, Mark I L Watling, Stevan Shaw
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Annals of the rheumatic diseases 78 (8) (2019)
Bruno Fautrel, Bruce Kirkham, Janet E Pope, Tsutomu Takeuchi, Carol Gaich, Amanda Quebe, Baojin Zhu, Inmaculada de la Torre, Francesco De Leonardis, Peter C Taylor
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. Journal of clinical medicine 8 (9) (2019)
Kristen Sweet, Bidisha Dasgupta, Dick de Vries, Ian Gourley, Benjamin Hsu, Matthew J Loza, Peter C Taylor
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Annals of the rheumatic diseases 78 (10) (2019)
Anne Lee, Marianne Sandvei, Hans Christian Asmussen, Marie Skougaard, Joanne Macdonald, Jakub Závada, Henning Bliddal, Peter C Taylor, Henrik Gudbergsen
The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies. JMIR research protocols 7 (7) (2018)
Dobrina N Hull, Helen Cooksley, Shilpa Chokshi, Richard O Williams, Sonya Abraham, Peter C Taylor
Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis research & therapy 18 (1) (2016)